Editas Medicine, Inc.
US ˙ NasdaqGS ˙ US28106W1036

Introduction

This page provides a comprehensive analysis of the known insider trading history of Erick Lucera. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Erick Lucera has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
Chief Financial Officer 66,100
US:EDIT / Editas Medicine, Inc. EVP, CHIEF FINANCIAL OFFICER 112,720
US:XAIR / Beyond Air, Inc. Director 43,608
US:BBLG / Bone Biologics Corporation Director 31,671
US:AVEO / AVEO Pharmaceuticals Inc Chief Financial Officer 218,800
US:VLRX / Valeritas, Inc. See Remarks 280,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Erick Lucera. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases EDIT / Editas Medicine, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EDIT / Editas Medicine, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EDIT / Editas Medicine, Inc. Insider Trades
Insider Sales EDIT / Editas Medicine, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EDIT / Editas Medicine, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-04 EDIT Lucera Erick 4,109 1.7108 4,109 1.7108 7,030 35 0.9801 -3,002 -42.71
2024-05-20 EDIT Lucera Erick 22,337 5.6142 22,337 5.6142 125,404

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EDIT / Editas Medicine, Inc. Insider Trades
Insider Purchases XAIR / Beyond Air, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EDIT / Editas Medicine, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-08-14 XAIR Lucera Erick 39,266 0.3964 1,963 7.9280 15,565 342 3.4000 -8,891 -57.12
2023-03-16 XAIR Lucera Erick 2,000 6.8170 100 136.3400 13,634

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XAIR / Beyond Air, Inc. Insider Trades
Insider Sales XAIR / Beyond Air, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EDIT / Editas Medicine, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XAIR / Beyond Air, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Erick Lucera as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-04-01 2025-03-31 4 DYN Dyne Therapeutics, Inc.
Common Stock
A - Award 66,100 66,100
2025-03-05 2025-03-04 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale -4,109 112,720 -3.52 1.71 -7,030 192,841
2024-08-15 2024-08-14 4 XAIR Beyond Air, Inc.
Common Stock
P - Purchase 39,266 43,608 904.33 0.40 15,565 17,286
2024-05-22 2024-05-20 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale -22,337 116,829 -16.05 5.61 -125,404 655,901
2024-03-05 2024-03-02 4 EDIT Editas Medicine, Inc.
Common Stock
A - Award 25,966 139,166 22.94
2024-03-05 2024-03-02 4 EDIT Editas Medicine, Inc.
Common Stock
A - Award 35,300 113,200 45.31
2023-05-18 2023-05-17 4 EDIT Editas Medicine, Inc.
Common Stock
A - Award 77,900 77,900
2023-03-20 2023-03-16 4 XAIR Beyond Air, Inc.
Common Stock
P - Purchase 2,000 4,342 85.40 6.82 13,634 29,599
2022-03-07 2022-03-03 4 XAIR Beyond Air, Inc.
Stock Option (right to buy)
A - Award 30,000 30,000
2022-02-28 2022-01-01 4 BBLG Bone Biologics Corp
Non-Employee Stock Option
A - Award 8,722 31,671 38.01
2022-02-28 2021-10-26 4 BBLG Bone Biologics Corp
Non-Employee Stock Option
A - Award 2,949 22,949 14.74
2022-02-17 2022-02-15 4 AVEO AVEO PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 218,800 218,800
2021-04-16 2021-02-05 4 AVEO AVEO PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 100,000 100,000
2021-03-08 2021-03-04 4 XAIR Beyond Air, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2021-03-03 2021-02-16 4 XAIR Beyond Air, Inc.
Tranche B Warrant (Right to Buy)
M - Exercise -1,171 0 -100.00
2021-03-03 2021-02-16 4 XAIR Beyond Air, Inc.
Common Stock
M - Exercise 1,171 2,342 100.00 4.25 4,977 9,954
2020-01-08 2020-01-06 4 AVEO AVEO PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 500,000 500,000
2019-03-08 2019-03-07 4 VLRX Valeritas Holdings Inc.
Employee Stock Option (Right to Buy)
A - Award 280,000 280,000
2018-11-20 2018-11-19 4 VLRX Valeritas Holdings Inc.
Employee Stock Option (Right to Buy)
A - Award 363,000 363,000
2018-08-15 2018-08-13 4 AITB AIT Therapeutics, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2018-04-30 2018-02-16 4 AITB AIT Therapeutics, Inc.
Tranche A Warrant (right to buy)
M - Exercise -1,171 0 -100.00
2018-04-30 2018-02-16 4 AITB AIT Therapeutics, Inc.
Tranche A Warrant (right to buy)
P - Purchase 1,171 1,171 0.01 12 12
2018-04-30 2018-02-16 4 AITB AIT Therapeutics, Inc.
Tranche B Warrant (right to buy)
P - Purchase 1,171 1,171 0.01 12 12
2018-04-30 2018-02-16 4 AITB AIT Therapeutics, Inc.
Common Stock
M - Exercise 1,171 1,171 4.25 4,977 4,977
2018-02-15 2018-02-13 4 VLRX Valeritas Holdings Inc.
Employee Stock Option (Right to Buy)
A - Award 27,000 27,000
2017-05-23 2017-05-22 4 VLRX Valeritas Holdings Inc.
Common Stock
P - Purchase 500 4,500 12.50 4.95 2,475 22,275
2017-05-23 2017-05-22 4 VLRX Valeritas Holdings Inc.
Common Stock
P - Purchase 1,000 4,000 33.33 4.95 4,950 19,800
2017-03-27 2017-03-23 4 VLRX Valeritas Holdings Inc.
Employee Stock Option (Right to Buy)
A - Award 73,800 73,800
2017-03-27 2017-03-23 4 VLRX Valeritas Holdings Inc.
Common Stock
P - Purchase 3,000 3,000 10.00 30,000 30,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)